Bausch + Lomb has begun distributing Lotemax SM, its gel drop formulation for the treatment of postoperative inflammation and pain following ocular surgery, in the United States, according to a press release.
Lotemax SM (loteprednol etabonate ophthalmic gel 0.38%) delivers a submicron particle size that penetrates better to the aqueous humor as compared with Lotemax Gel 0.5%.
“Lotemax SM is the culmination of our clinical experience with the loteprednol etabonate compound for more than two decades,” Joe Gordon, U.S. president, Bausch + Lomb, said in the release. “We are
Uncategorized